Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis

Not Applicable

Active, not recruiting

• Conditions: Aortic Stenosis
• Interventions: Device: TaurusOne® transcatheter aortic valve replacement system

• Registration Number: NCT04815785
• Lead Sponsor: Peijia Medical Technology (Suzhou) Co., Ltd.

Brief Summary

To observe and evaluate the safety and efficacy of TaurusOne® transcatheter aortic valve system in patients with severe calcific aortic stenosis through a prospective, multicenter clinical trial using objective performance criteria.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-09-22
• Primary Completion: 2020-05-11
• Study First Submitted: 2021-03-06
• Study First Submitted QC: 2021-03-22
• Study First Posted: 2021-03-25
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-20
• Last Update Posted: 2023-10-24
• Study Completion: 2024-05-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Patients who voluntarily participate and sign the informed consent and are able to comply with the entire trial process;

• Age ≥ 70 years;

• Patients with severe calcific aortic stenosis confirmed by echocardiography (Transaortic flow velocity ≥ 4.0 m/s, or aortic-valve gradient ≥ 40 mmHg (1 mmHg = 0.133 kPa), or aortic valve area < 0.8 cm2, or effective orifice area < 0.5 cm2/m2);

• Patients who have symptoms obviously caused by aortic stenosis, NYHA Class II or worse;

• Patients who are unsuitable for conventional surgery evaluated by the cardiac team (including at least two cardiovascular surgeons) [13] *;

• Life expectancy after implantation of prosthetic valve is more than one year evaluated by the cardiac team (including at least two cardiac surgeons);

• Aortic annulus diameter ≥ 18 mm and ≤ 29 mm (measured by cardiac CT);

• Ascending aorta diameter < 50 mm

  *: If the patient meets any of the following criteria judged by a multidisciplinary cardiac team composed of cardiologists and cardiovascular surgeons, radiologists, anesthesiologists, etc. (at least two cardiovascular surgeons), the patient will be identified as unsuitable for conventional surgery (at least STS ≥ 8 points):

• Estimated risk of surgery-related death or disability > 50% within 1 year;

• ≥3 major organ damage that could not be improved by surgery;

• Obstacles related to surgical procedures judged as serious

Exclusion Criteria

• Patients with bacteremia or toxemia;
• Previous endocarditis or active endocarditis;
• Acute myocardial infarction (Q-wave MI, or non-Q-wave MI with elevated creatine kinase isoenzyme and troponin T) within 30 days;
• Any intracardiac mass, left ventricular or atrial thrombus, vegetation on echocardiography;
• Symptomatic atrial fibrillation that cannot be improved by drug therapy;
• Familial hypertrophic cardiomyopathy;
• Mitral or tricuspid valve insufficiency (grade II regurgitation or higher);
• Previous aortic valve graft (mechanical or bioprosthetic valve);
• Known allergies to contrast agents, aspirin, heparin, ticlopidine drugs, nitinol shape memory alloy, or bovine products;
• Known contraindications or allergies to anticoagulant regimens, or inability to use anticoagulants throughout the trial;
• Other serious diseases that may reduce life expectancy to less than 12 months (such as clinically recurrent or metastatic cancer, congestive heart failure, etc.);
• Current substance abuse problems (e.g., alcohol, cocaine, heroin, etc.);
• Scheduled to undergo surgery that may result in protocol noncompliance or confounding in data interpretation.
• Cerebrovascular accident (CVA) in the past 6 months;
• Patients with common carotid artery or internal carotid artery or vertebral artery stenosis (>70%);
• White blood cell count <3×109/L, platelet count <50×109/L;
• Hemoglobin < 90 g/L;
• Patients with severe coagulopathy;
• Severe left ventricular dysfunction, left ventricular ejection fraction < 20%;
• Abdominal or thoracic aortic aneurysm;
• Hepatic encephalopathy or acute active hepatitis;
• On dialysis or baseline creatinine level > 2.5 mg/dL (221 μ mol/L);
• Bleeding tendency or history of coagulation disease or refusal of blood transfusion;
• Patients with active peptic ulcer or active gastrointestinal (GI) bleeding;
• Patients with neurological diseases that seriously affect mobility and activities of daily living;
• Patients with mental illness or psychological disorders who are unable to communicate effectively;
• Patients who need emergency surgery for any reason;
• Patients who have participated in other drug or medical device clinical trials within 3 months prior to screening;
• Other conditions that make the patient ineligible to participate in this clinical trial in judgement of investigators

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A single set of test	TaurusOne® transcatheter aortic valve replacement system	The experimental apparatus consisted of artificial aortic valve, transporter and loading system

Primary Outcome Measures

Name	Time	Method
All-cause mortality at 12 months	12 months	All-cause mortality

Secondary Outcome Measures

Name	Time	Method
Device success rate (Immediate after procedure)	Immediate after procedure	* Successful delivery and release of vascular access and prosthetic aortic valve, and successful withdrawal of the delivery catheter; * Accurate placement of prosthetic aortic valve at the anatomical site; * Prosthetic aortic valve meets the desired requirements (mean valve gradient \< 20 mm Hg or maximal flow velocity \< 3 m/s; No severe prosthetic valve regurgitation or perivalvular leak)
Procedure success rate	72 hours after procedure/prior to discharge	A successful procedure is defined as successful implantation of the prosthetic aortic valve at the correct anatomical site 72 hours after the operation or before discharge without severe prosthetic valve regurgitation or perivalvular leak.
Cardiac function improvement	30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years	NYHA functional classification

Trial Locations

Locations (1)

Peiga Medical Technology (Suzhou) Co., Ltd; 🇨🇳 Suzhou, Jiangsu, China